A systematic review in BMJ Evidence-Based Medicine reveals only 10% of treatments for low back pain offer genuine relief.
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbus ...